Complete financial analysis of Replimune Group, Inc. (REPL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Replimune Group, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Chongqing Three Gorges Water Conservancy and Electric Power Co., Ltd. (600116.SS) Income Statement Analysis – Financial Results
- Decora S.A. (DCR.WA) Income Statement Analysis – Financial Results
- WOLVES HAND CO LTD (194A.T) Income Statement Analysis – Financial Results
- Energy & Technology, Corp. (ENGT) Income Statement Analysis – Financial Results
- CompuGroup Medical SE & Co. KGaA (0MSD.L) Income Statement Analysis – Financial Results
Replimune Group, Inc. (REPL)
About Replimune Group, Inc.
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.66M | 2.45M | 4.58M | 4.14M | 1.81M | 148.00K | 109.00K | 122.00K |
| Gross Profit | -2.66M | -2.45M | -4.58M | -4.14M | -1.81M | -148.00K | -109.00K | -122.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 174.96M | 126.53M | 79.55M | 56.75M | 38.76M | 22.17M | 13.52M | 6.94M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 23.20M | 17.44M | 8.77M | 5.71M | 2.71M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 59.81M | 50.55M | 38.77M | 23.20M | 17.44M | 8.77M | 5.71M | 2.71M |
| Other Expenses | 0.00 | -5.68M | -1.06M | -665.00K | -16.00K | 451.00K | -2.06M | 626.00K |
| Operating Expenses | 234.77M | 174.17M | 115.14M | 77.15M | 53.11M | 28.42M | 16.96M | 8.21M |
| Cost & Expenses | 234.77M | 174.17M | 115.14M | 77.15M | 53.11M | 28.42M | 16.96M | 8.21M |
| Interest Income | 16.70M | 10.01M | 390.00K | 916.00K | 2.42M | 2.59M | 288.00K | 25.00K |
| Interest Expense | 0.00 | 4.16M | 2.22M | 3.06M | 1.92M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.66M | 2.45M | 4.58M | 4.14M | 1.81M | 148.00K | 109.00K | 122.00K |
| EBITDA | -230.20M | -170.30M | -114.41M | -76.48M | -52.60M | -28.27M | -16.85M | -8.08M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -234.77M | -177.08M | -118.31M | -79.96M | -56.20M | -30.95M | -19.23M | -9.65M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 19.39M | 3.08M | 278.00K | -915.00K | 3.57M | 112.00K | -473.00K | 1.94M |
| Income Before Tax | -215.39M | -174.00M | -118.04M | -80.87M | -52.63M | -30.83M | -19.70M | -7.70M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 408.00K | 288.00K | 1.16M | 2.40M | 1.90M | 451.00K | -2.06M | 125.00K |
| Net Income | -215.79M | -174.28M | -118.04M | -80.87M | -52.63M | -30.83M | -19.70M | -7.70M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.24 | -2.99 | -2.26 | -1.75 | -1.54 | -1.33 | -0.64 | -0.36 |
| EPS Diluted | -3.24 | -2.99 | -2.26 | -1.75 | -1.54 | -1.33 | -0.64 | -0.25 |
| Weighted Avg Shares Out | 66.57M | 58.21M | 52.21M | 46.25M | 34.26M | 23.20M | 30.84M | 21.51M |
| Weighted Avg Shares Out (Dil) | 66.57M | 58.21M | 52.21M | 46.25M | 34.26M | 23.20M | 30.84M | 30.84M |
Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
RP1 monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent and complete response rate of nearly 22 percent in evaluable patients RP1 monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35...
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced the grant of inducement equity awards to Carolyn Trott, the...
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercialization Preparations on track to submit RP1 biologics license application (BLA) in 2H 2024 WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE)...
How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%
The average of price targets set by Wall Street analysts indicates a potential upside of 50.2% in Replimune Group, Inc. (REPL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate...
What Makes Replimune Group, Inc. (REPL) a New Buy Stock
Replimune Group, Inc. (REPL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High?
The consensus price target hints at a 70.6% upside potential for Replimune Group, Inc. (REPL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness...
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
WOBURN, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31,...
Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference
WOBURN, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present...
Why Is Replimune (REPL) Stock Down 48% Today?
Replimune (NASDAQ: REPL ) stock is falling hard on Tuesday after the clinical-stage biotechnology company shared a primary analysis of its CERPASS trial. This trial is evaluating RP1 alongside cemiplimab in the treatment of locally advanced or metastatic cutaneous squamous cell...
Replimune shares plunge as skin cancer therapy fails to meet primary clinical-trial goals
Replimune Group Inc. shares REPL, +5.21% dropped more than 40% premarket on Tuesday after the biotech company said an investigational cancer therapy had failed to meet its primary goals in a clinical trial in skin cancer. The therapy, RP1, was...
Source: https://incomestatements.info
Category: Stock Reports